Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo bolus & placebo infusion Clear all
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Neurochemical Mechanisms of the Awake vs. Anesthetized Brain

NCT05435560
View directory record Official record
Conditions
Anesthesia, Healthy
Interventions
Dexmedetomidine, Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Impaired Brain Blood Flow With Aging

NCT03775382
View directory record Official record
Conditions
Aging
Interventions
Ascorbic Acid, Normal Saline
Other
Lead sponsor
University of Delaware
Other
Eligibility
18 Years to 79 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
49
States / cities
Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Role of Opioidergic Systems in Breathing Based Analgesia

NCT03419858
View directory record Official record
Conditions
Pain
Interventions
Mindfulness Meditation, Placebo Meditation, Slow-Breathing, Naloxone, Saline
Behavioral · Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Bortezomib, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
11
States / cities
Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 7, 2026, 4:28 AM EDT
Withdrawn Phase 3 Interventional

Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

NCT00684164
View directory record Official record
Conditions
Hyponatremia
Interventions
Conivaptan, D5
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 7, 2026, 4:28 AM EDT
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

DPP4 Inhibition & Beta Cell Function

NCT02683187
View directory record Official record
Conditions
Healthy
Interventions
Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
35 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide (LY3298176) in Healthy Participants

NCT03375463
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 7, 2026, 4:28 AM EDT
Withdrawn Not applicable Interventional

Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension

NCT02101047
View directory record Official record
Conditions
Complications; Cesarean Section, Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Interventions
Phenylephrine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 7, 2026, 4:28 AM EDT
Withdrawn Phase 4 Interventional

Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision

NCT05082155
View directory record Official record
Conditions
Surgical Incision, Pain, Postoperative, Pain, Acute
Interventions
Bupivacaine 0.25%, Normal Saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 7, 2026, 4:28 AM EDT
Recruiting Phase 4 Interventional

Effect of Magnesium Sulfate Bolus on Intraoperative Neuromonitoring

NCT04938765
View directory record Official record
Conditions
Intraoperative Neurophysiological Monitoring, Magnesium Sulfate
Interventions
Magnesium sulfate, Normal Saline
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Not applicable Interventional Results available

Lidocaine and Prevention of Chronic Pain

NCT01619852
View directory record Official record
Conditions
Surgery
Interventions
.9 normal saline placebo, Group L (lidocaine)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 7, 2026, 4:28 AM EDT
Withdrawn Phase 2 Interventional

Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery

NCT01930877
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo (normal saline)
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 7, 2026, 4:28 AM EDT
Terminated Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects

NCT05253209
View directory record Official record
Conditions
Ventricular Septal Defect, Atrioventricular Septal Defect, Primum Atrial Septal Defect
Interventions
L-citrulline, Plasmalyte A
Drug
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
Up to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 4 Interventional

Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department

NCT00559338
View directory record Official record
Conditions
Heart Failure, Congestive, Cardiomyopathy
Interventions
recombinant B-type, natriuretic peptide, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT05712356
View directory record Official record
Conditions
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions
certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571
View directory record Official record
Conditions
Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions
cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
11,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 7, 2026, 4:28 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Ketamine on Postoperative Clinical Outcomes

NCT01365195
View directory record Official record
Conditions
Colorectal Surgery
Interventions
Placebo, Ketamine high-dose, Ketamine low-dose
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 7, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

NCT04715022
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Ascorbic acid solution (American Regent Laboratories Inc.), Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 7, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing

NCT03330457
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV)
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 7, 2026, 4:28 AM EDT
Completed Phase 3 Interventional

A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

NCT01662869
View directory record Official record
Conditions
Gastric Cancer
Interventions
5-Fluoruracil, Folinic acid, Onartuzumab, Oxaliplatin, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 7, 2026, 4:28 AM EDT